DRNA - Dicerna slips from peak after data for liver disease trial; RBC analyst shrugs off impact

alexsl/iStock via Getty Images Having closed at the highest level since early 2014 on Tuesday, Dicerna Pharmaceuticals (DRNA) dropped ~3.8% today after the company announced interim data for belcesiran in Alpha-1 antitrypsin deficiency-associated liver disease ((AATLD)). Despite the “numerically inferior” mean maximum serum AAT reductions in the Phase 1 trial, RBC analyst Luca Issi pointed to the difficulty in comparing the numbers given the smaller size of the study, which has yet to generate the data from the highest dose cohort. With a price target of $35.00 per share, Issi continues to rate Dicerna with an outperform recommendation citing the pivotal trial data anticipated “any day now” for the company’s lead asset nedosiran in patients with primary hyperoxaluria ((PH)). The company expects to submit a marketing application for nedosiran in Q4 2021 based on its clinical program for the drug in PH.

For further details see:

Dicerna slips from peak after data for liver disease trial; RBC analyst shrugs off impact